UNITY Biotechnology Inc To Discuss Phase 2 BEHOLD Program Update Call Transcript
Good morning, and welcome to the UNITY Biotechnology Investor Call on the Phase II Clinical Update in the BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema. (Operator Instructions) As a reminder, this call is being recorded, and a replay will be made available on the UNITY website following the conclusion of the event.
I'd now like to turn the call over to Lynne Sullivan, Chief Financial Officer of UNITY Biotechnology. Please go ahead, Lynne.
Thanks, Tara. Good morning, and thank you for joining UNITY Biotechnology's conference call to review 24-week data from the Phase II BEHOLD study of UBX1325 in patients with DME.
With me on today's call is Anirvan Ghosh, the CEO of UNITY Biotechnology; Jamie Dananberg, our Chief Medical Officer; and myself, Lynne Sullivan, the Chief Financial Officer. We're fortunate to have Dr. Arshad Khanani, Director
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |